Psoriasis

Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
New Study Looks At Obscure Cannabinoids For Treating Psoriasis, Eczema And Acne
The Key To Perfect Hair? Myths And Benefits Of CBD For Hair Care
New Study Looks At Obscure Cannabinoids For Treating Psoriasis, Eczema And Acne
The Key To Perfect Hair? Myths And Benefits Of CBD For Hair Care
Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate
Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study

Psoriasis Recent News

Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has 
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
The FDA has accepted Arcutis Biotherapeutics Inc's (NASDAQ:
Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level
The FDA has approved Amgen Inc's (NASDAQ:
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022
Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week cycle of treatment with Piclidenoson 
vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%
vTv Therapeutics Inc (NASDAQ: VTVT) has 
Amgen's Otezla Meets Primary Goal In Late-Stage Genital Psoriasis Study
Amgen Inc (NASDAQ: AMGN) 
Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis
The 
Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial
Dermata Stock Jumps On Positive Psoriasis Candidate Data
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis
Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study
vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile
Why Are Dermata Therapeutics Shares Trading Higher Today?
Soligenix To Test Synthetic Hypericin In Psoriasis Patients
UCB Gets EU Approval For Bimekizumab In Psoriasis
Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients
Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications
Bristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows
Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation
Can-Fite Expands Mid-Stage COVID-19 Study To Europe
Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing
Aditx Therapeutics Stock Is Trading Higher On Initiating Human Trials With Psoriasis Candidate By 2021
Aditx Therapeutics Inc (NASDAQ: ADTX) is 

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved